JAGSNPHARMJAGSNPHARM Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverCompetitive Position
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
8 / 100
+3 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in competitive position. No immediate concerns are visible. Risk is increasing at a faster pace.

19.2th %ile (Sector)Accel: +2 Qtrs
Updated2026-06-02
Market View
₹201.74▲0.07%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Competitive Position
+7.7 pts
Final Composite Risk8 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 8 over 12 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Relative Growth Weakness
  • Working Capital Expansion
What to Watch Next Quarter
  • Operating profit margins
  • Inventory turnover
  • Working capital efficiency

Active Risk Objects (4)

CriticalHigh
Profit Collapse
📊 Earnings QualityQuarterlyActive for 1 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ3 FY2026
JAGSNPHARM: Net Profit collapsed by 65.8% from FY2025 Q3 to FY2026 Q3.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ2 FY2024
Inventory growth (4.3%) significantly outpaced revenue growth (-2.5%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ4 FY2026
Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2025
Working capital expansion detected: Receivable days increased by -9.8%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)2.557.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+58.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹201.74(+0.07%)
1M Divergence-6.37%
1 Week-2.96%
1 Month-4.1%
6 Months-7.5%
1 Year-14.03%
2 Year+58.13%
3 Year+42.79%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in competitive position remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

JAGSNPHARM • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.3%
Trend QualityEarly Base
Phase Progression
Phase Progression Score15%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing3%
CoinTree Momentum
Composite Z-Score-0.0185σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#1028 of 2716
Top 37.85% in momentum strength
Timeframe Sparklines
1W-3.0%
1M-4.1%
6M-7.5%
Weinstein Indicators
150 DMA₹193.91
200 DMA₹203.77
150 DMA Slope-0.9520%Declining
Relative Strength-2.01%Lagging
Relative Turnover (RTR)1.5059
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

JAGSNPHARMJAGSNPHARM
8 Risk
Sector %ile19th
Delta+3
Active Flags4
Accel+2
Competitive Position

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
4.948.8th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Relative Growth Weakness

2025

Working Capital Expansion

2024

Inventory Stress

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20262994347-
FY20252775555-
FY20242182235-
FY20232422740-